Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Tolvaptan | hsa00030 | Pentose phosphate pathway | 7.65E-04 | 3 | P06744, P60891, P37837 | GPI, PRPS1, TALDO1 | More | | Tolvaptan | hsa00061 | Fatty acid biosynthesis | 4.83E-02 | 1 | P33121 | ACSL1 | More | | Tolvaptan | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Tolvaptan | hsa00220 | Arginine biosynthesis | 3.83E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Tolvaptan | hsa00310 | Lysine degradation | 2.59E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Tolvaptan | hsa00500 | Starch and sucrose metabolism | 1.33E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Tolvaptan | hsa00512 | Mucin type O-glycan biosynthesis | 4.86E-02 | 2 | O95395, Q9NY28 | GCNT3, GALNT8 | More | | Tolvaptan | hsa00513 | Various types of N-glycan biosynthesis | 4.83E-02 | 1 | Q9NR34 | MAN1C1 | More | | Tolvaptan | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Tolvaptan | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Tolvaptan | hsa00591 | Linoleic acid metabolism | 1.95E-03 | 1 | P11712 | CYP2C9 | More | | Tolvaptan | hsa00630 | Glyoxylate and dicarboxylate metabolism | 9.62E-04 | 3 | P40925, P40926, P15104 | MDH1, MDH2, GLUL | More | | Tolvaptan | hsa00730 | Thiamine metabolism | 2.43E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Tolvaptan | hsa00830 | Retinol metabolism | 4.01E-03 | 4 | P00352, Q9BPW9, O75911, P11712 | ALDH1A1, DHRS9, DHRS3, CYP2C9 | More | | Tolvaptan | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Tolvaptan | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Tolvaptan | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Tolvaptan | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Tolvaptan | hsa01200 | Carbon metabolism | 7.69E-03 | 3 | P06744, P37837, P40926 | GPI, TALDO1, MDH2 | More | | Tolvaptan | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | | Tolvaptan | hsa01523 | Antifolate resistance | 2.04E-02 | 2 | P04818, P18054 | TYMS, ALOX12 | More | | Tolvaptan | hsa01524 | Platinum drug resistance | 4.42E-02 | 3 | P10415, Q13489, P23025 | BCL2, BIRC3, XPA | More | | Tolvaptan | hsa02010 | ABC transporters | 1.98E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Tolvaptan | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | Tolvaptan | hsa03013 | RNA transport | 6.93E-08 | 16 | O14980, P52298, O14893, P61326, Q15287, Q9UBU9, Q7Z3B4, P35658, P63279, Q14152, P55884, O15371, P20042, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, GEMIN2, MAGOH, RNPS1, NXF1, NUP54, NUP214, UBE2I, EIF3A, EIF3B, EIF3D, EIF2S2, EIF4A2, EIF4B, TACC3 | More | | Tolvaptan | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Tolvaptan | hsa03040 | Spliceosome | 5.33E-05 | 12 | Q14562, O43143, O60508, P17844, Q15427, P51991, P38159, P61978, Q07955, Q01130, Q13243, P11142 | DHX8, DHX15, CDC40, DDX5, SF3B4, HNRPA3, RBMX, HNRPK, SFRS1, SFRS2, SFRS5, HSPA8 | More | | Tolvaptan | hsa03060 | Protein export | 1.43E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Tolvaptan | hsa03320 | PPAR signaling pathway | 4.55E-02 | 2 | O00767, Q02318 | SCD, CYP27A1 | More | | Tolvaptan | hsa04012 | ErbB signaling pathway | 3.74E-02 | 3 | P21860, Q13557, O14944 | ERBB3, CAMK2D, EREG | More | | Tolvaptan | hsa04014 | Ras signaling pathway | 8.19E-04 | 9 | Q9NRA1, Q13009, Q15283, P61586, P0DP23, P62873, P63218, P50151, P19174 | PDGFC, TIAM1, RASA2, RHOA, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Tolvaptan | hsa04020 | Calcium signaling pathway | 6.50E-04 | 6 | Q96DU7, P45880, Q13557, P21860, P51828, P23634 | ITPKC, VDAC2, CAMK2D, ERBB3, ADCY7, ATP2B4 | More | | Tolvaptan | hsa04022 | cGMP-PKG signaling pathway | 4.72E-02 | 4 | Q99941, P23634, P51828, P45880 | CREBL1, ATP2B4, ADCY7, VDAC2 | More | | Tolvaptan | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | Tolvaptan | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.01E-04 | 9 | P09341, P19875, P25024, P02775, P25025, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCL2, CXCR1, PPBP, CXCR2, XCL1, XCL2, IL10RA, IL2RB | More | | Tolvaptan | hsa04062 | Chemokine signaling pathway | 2.97E-06 | 18 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P07948, P42338, P19174, P62873, P63218, P50151, P43250, Q08881, Q13009, P14598, P42224, P25963 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, GRK6, ITK, TIAM1, NCF1, STAT1, NFKBIA | More | | Tolvaptan | hsa04064 | NF-kappa B signaling pathway | 9.61E-10 | 20 | P10415, Q13489, O00463, Q13546, P14778, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q8WV28, Q13315, P24522, P09341, P19875, Q06643, Q9UNE0 | BCL2, BIRC3, TRAF5, RIPK1, IL1R1, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, BLNK, ATM, GADD45A, CXCL1, CXCL2, LTB, EDAR | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.766 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.706 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.713 | P08235 | NR3C2 | Mineralocorticoid receptor | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.868 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.832 | P06737 | PYGL | Glycogen phosphorylase, liver form | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.924 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.717 | P08235 | NR3C2 | Mineralocorticoid receptor | Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | -0.749 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P06737 | PYGL | Glycogen phosphorylase, liver form | P01375 | TNF | Tumor necrosis factor | 0.759 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | P08235 | NR3C2 | Mineralocorticoid receptor | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.708 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.723 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.783 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.967 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.751 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q8WV28 | BLNK | B-cell linker protein | -0.706 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | Q8WV28 | BLNK | B-cell linker protein | -0.746 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q13315 | ATM | Serine-protein kinase ATM | 0.723 | P06737 | PYGL | Glycogen phosphorylase, liver form | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.822 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.734 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09341 | CXCL1 | Growth-regulated alpha protein | 0.74 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.789 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 | Q13547 | HDAC1 | Histone deacetylase 1 | Q06643 | LTB | Lymphotoxin-beta | 0.74 | P08235 | NR3C2 | Mineralocorticoid receptor | Q9UNE0 | EDAR | Tumor necrosis factor receptor superfamily member EDAR | 0.819 |
| Tolvaptan | hsa04070 | Phosphatidylinositol signaling system | 2.37E-03 | 6 | P19174, P0DP23, P23743, Q86XP1, P27987, Q96DU7 | PLCG1, CALM1, DGKA, DGKH, ITPKB, ITPKC | More | | Tolvaptan | hsa04071 | Sphingolipid signaling pathway | 4.34E-06 | 9 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2, P01042 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2, KNG1 | More | | Tolvaptan | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Tolvaptan | hsa04080 | Neuroactive ligand-receptor interaction | 1.37E-04 | 12 | P08311, Q15722, P21453, Q9H228, O00398, P25116, P21462, P21730, Q16581, P07550, P01042, P35318 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, F2R, FPR1, C5AR1, C3AR1, ADRB2, KNG1, ADM | More | | Tolvaptan | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Tolvaptan | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | Tolvaptan | hsa04141 | Protein processing in endoplasmic reticulum | 1.75E-05 | 13 | P18848, P30101, Q15437, P60604, Q99941, O75460, P11142, Q9H3Z4, P07900, P08238, Q9NR31, Q9H173, Q9UNL2 | ATF4, PDIA3, SEC23B, UBE2G2, CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1, HSP90AB1, SAR1A, SIL1, SSR3 | More | | Tolvaptan | hsa04145 | Phagosome | 9.44E-04 | 11 | P11215, Q15080, P14598, Q71U36, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | ITGAM, NCF4, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Tolvaptan | hsa04151 | PI3K-Akt signaling pathway | 3.91E-03 | 7 | P62753, P27348, P07900, P22105, Q99941, P18848, O00141 | RPS6, YWHAQ, HSP90AA1, TNXB, CREBL1, ATF4, SGK | More | | Tolvaptan | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | | Tolvaptan | hsa04211 | Longevity regulating pathway | 9.85E-04 | 6 | Q12778, P51828, Q99941, P18848, Q9UEF7, Q96KQ7 | FOXO1, ADCY7, CREBL1, ATF4, KL, EHMT2 | More | | Tolvaptan | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Tolvaptan | hsa04215 | Apoptosis - multiple species | 3.01E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Tolvaptan | hsa04217 | Necroptosis | 2.93E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | Tolvaptan | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.68E-03 | 5 | P51828, Q99941, P18848, Q13557, P23634 | ADCY7, CREBL1, ATF4, CAMK2D, ATP2B4 | More | | Tolvaptan | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | | Tolvaptan | hsa04340 | Hedgehog signaling pathway | 8.75E-05 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Tolvaptan | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Tolvaptan | hsa04371 | Apelin signaling pathway | 7.95E-04 | 7 | P62873, P63218, P50151, Q13370, Q14344, P84022, P0DP23 | GNB1, GNG5, GNG10, PDE3B, GNA13, SMAD3, CALM1 | More | | Tolvaptan | hsa04380 | Osteoclast differentiation | 1.81E-02 | 4 | Q9UQC2, Q16539, Q8WV28, Q15080 | GAB2, MAPK14, BLNK, NCF4 | More | | Tolvaptan | hsa04510 | Focal adhesion | 4.60E-02 | 4 | P16144, Q15942, Q13489, P10415 | ITGB4, ZYX, BIRC3, BCL2 | More | | Tolvaptan | hsa04530 | Tight junction | 2.45E-03 | 6 | Q8TEU7, P16989, P56750, O00501, Q14247, P24844 | RAPGEF6, CSDA, CLDN17, CLDN5, CTTN, MYL9 | More | | Tolvaptan | hsa04540 | Gap junction | 1.08E-02 | 4 | Q13509, P68371, Q71U36, Q9NRA1 | TUBB3, TUBB2C, TUBA1A, PDGFC | More | | Tolvaptan | hsa04610 | Complement and coagulation cascades | 3.01E-06 | 5 | P25116, P01042, P00734, P0C0L4, Q16581 | F2R, KNG1, F2, C4A, C3AR1 | More | | Tolvaptan | hsa04612 | Antigen processing and presentation | 1.13E-05 | 9 | P13765, P48382, P01730, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, CD4, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P14780 | MMP9 | Matrix metalloproteinase-9 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.714 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.73 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 | P14780 | MMP9 | Matrix metalloproteinase-9 | P48382 | RFX5 | DNA-binding protein RFX5 | -0.874 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P48382 | RFX5 | DNA-binding protein RFX5 | -0.738 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P14780 | MMP9 | Matrix metalloproteinase-9 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.867 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.838 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.853 | P14780 | MMP9 | Matrix metalloproteinase-9 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.867 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.838 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.853 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.856 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.863 | P14780 | MMP9 | Matrix metalloproteinase-9 | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.792 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.741 | P14780 | MMP9 | Matrix metalloproteinase-9 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.742 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.816 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.92 | P14780 | MMP9 | Matrix metalloproteinase-9 | P01375 | TNF | Tumor necrosis factor | 0.897 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 |
| Tolvaptan | hsa04613 | Neutrophil extracellular trap formation | 6.36E-07 | 20 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, Q6FI13, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | O60603 | TLR2 | Toll-like receptor 2 | 0.836 | P14780 | MMP9 | Matrix metalloproteinase-9 | O60603 | TLR2 | Toll-like receptor 2 | 0.89 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60603 | TLR2 | Toll-like receptor 2 | 0.867 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | O60603 | TLR2 | Toll-like receptor 2 | -0.717 | P06737 | PYGL | Glycogen phosphorylase, liver form | P05164 | MPO | Myeloperoxidase | 0.858 | P14780 | MMP9 | Matrix metalloproteinase-9 | P05164 | MPO | Myeloperoxidase | 0.812 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P05164 | MPO | Myeloperoxidase | 0.711 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P05164 | MPO | Myeloperoxidase | -0.866 | P06737 | PYGL | Glycogen phosphorylase, liver form | P08246 | ELA2 | Neutrophil elastase | 0.817 | P14780 | MMP9 | Matrix metalloproteinase-9 | P08246 | ELA2 | Neutrophil elastase | 0.859 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.703 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P08246 | ELA2 | Neutrophil elastase | -0.76 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.813 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.9 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.825 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | -0.819 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13547 | HDAC1 | Histone deacetylase 1 | -0.742 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q92769 | HDAC2 | Histone deacetylase 2 | -0.746 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P04908 | H2AC4; H2AC8 | Histone H2A type 1-B/E | 0.734 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.74 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.737 | P11712 | CYP2C9 | Cytochrome P450 2C9 | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.754 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | P11712 | CYP2C9 | Cytochrome P450 2C9 | O60814 | H2BC12 | Histone H2B type 1-K | 0.728 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.913 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.845 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.836 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.869 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.764 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | -0.731 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20160 | AZU1 | Azurocidin | 0.781 | P14780 | MMP9 | Matrix metalloproteinase-9 | P20160 | AZU1 | Azurocidin | 0.734 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20160 | AZU1 | Azurocidin | -0.799 | P06737 | PYGL | Glycogen phosphorylase, liver form | P08311 | CTSG | Cathepsin G | 0.829 | P14780 | MMP9 | Matrix metalloproteinase-9 | P08311 | CTSG | Cathepsin G | 0.79 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P08311 | CTSG | Cathepsin G | 0.709 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P08311 | CTSG | Cathepsin G | -0.811 | P06737 | PYGL | Glycogen phosphorylase, liver form | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.852 | P14780 | MMP9 | Matrix metalloproteinase-9 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.928 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.893 | P06737 | PYGL | Glycogen phosphorylase, liver form | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.888 | P14780 | MMP9 | Matrix metalloproteinase-9 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.942 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 1 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | -0.772 | P06737 | PYGL | Glycogen phosphorylase, liver form | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.833 | P14780 | MMP9 | Matrix metalloproteinase-9 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.912 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.842 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | O43315 | AQP9 | Aquaporin-9 | -0.764 | P06737 | PYGL | Glycogen phosphorylase, liver form | O43315 | AQP9 | Aquaporin-9 | 0.897 | P14780 | MMP9 | Matrix metalloproteinase-9 | O43315 | AQP9 | Aquaporin-9 | 0.837 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O43315 | AQP9 | Aquaporin-9 | 0.915 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | -0.744 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.778 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 |
| Tolvaptan | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Tolvaptan | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | | Tolvaptan | hsa04621 | NOD-like receptor signaling pathway | 5.89E-04 | 14 | Q16539, Q14643, P01568, Q13489, P10599, Q9H1Y0, P43490, O00463, P10415, Q13546, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, IFNA21, BIRC3, TXN, ATG5, PBEF1, TRAF5, BCL2, RIPK1, RNASEL, TNF, CXCL1, DEFA4 | More | | Tolvaptan | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Tolvaptan | hsa04623 | Cytosolic DNA-sensing pathway | 1.93E-04 | 3 | P01568, Q13546, P25963 | IFNA21, RIPK1, NFKBIA | More | | Tolvaptan | hsa04625 | C-type lectin receptor signaling pathway | 4.80E-02 | 6 | Q9ULY5, P20749, Q14643, P01375, Q13191, Q16539 | CLEC4E, BCL3, ITPR1, TNF, CBLB, MAPK14 | More | | Tolvaptan | hsa04640 | Hematopoietic cell lineage | 1.71E-06 | 14 | P13612, P14778, P27930, P11215, P15144, P11836, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ITGAM, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF | More | | Tolvaptan | hsa04650 | Natural killer cell mediated cytotoxicity | 2.82E-07 | 13 | P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, P26715 | PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.809 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.81 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.869 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.856 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.863 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.879 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.762 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.893 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.838 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.853 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.838 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.853 |
| Tolvaptan | hsa04657 | IL-17 signaling pathway | 1.59E-05 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.924 | P14780 | MMP9 | Matrix metalloproteinase-9 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.917 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.875 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.778 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | P06737 | PYGL | Glycogen phosphorylase, liver form | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.815 | P14780 | MMP9 | Matrix metalloproteinase-9 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.75 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.781 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09341 | CXCL1 | Growth-regulated alpha protein | 0.74 | P14780 | MMP9 | Matrix metalloproteinase-9 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.771 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.781 | P06737 | PYGL | Glycogen phosphorylase, liver form | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.917 | P14780 | MMP9 | Matrix metalloproteinase-9 | P14780 | MMP9 | Matrix metalloproteinase-9 | 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.778 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.942 | P06737 | PYGL | Glycogen phosphorylase, liver form | P80188 | LCN2 | Neutrophil gelatinase-associated lipocalin | 0.706 | P14780 | MMP9 | Matrix metalloproteinase-9 | P80188 | LCN2 | Neutrophil gelatinase-associated lipocalin | 0.888 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P80188 | LCN2 | Neutrophil gelatinase-associated lipocalin | 0.721 | P06737 | PYGL | Glycogen phosphorylase, liver form | P01375 | TNF | Tumor necrosis factor | 0.759 | P14780 | MMP9 | Matrix metalloproteinase-9 | P01375 | TNF | Tumor necrosis factor | 0.897 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 |
| Tolvaptan | hsa04658 | Th1 and Th2 cell differentiation | 4.45E-16 | 15 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, Q14765, P42226, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT4, STAT6, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q04759 | PRKCQ | Protein kinase C theta type | -0.787 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | P14780 | MMP9 | Matrix metalloproteinase-9 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.745 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | P14780 | MMP9 | Matrix metalloproteinase-9 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.778 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.736 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.861 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.768 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.742 | P06737 | PYGL | Glycogen phosphorylase, liver form | P42226 | STAT6 | Signal transducer and activator of transcription 6 | 0.852 | P06737 | PYGL | Glycogen phosphorylase, liver form | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.753 | P14780 | MMP9 | Matrix metalloproteinase-9 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.747 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.767 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.85 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.738 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.808 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q13547 | HDAC1 | Histone deacetylase 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.817 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.861 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.735 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.816 | P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | P14780 | MMP9 | Matrix metalloproteinase-9 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.714 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.73 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.884 |
| Tolvaptan | hsa04659 | Th17 cell differentiation | 1.50E-11 | 18 | P25963, Q04759, Q16539, P19174, P01730, P06239, P42224, P42226, P14784, P13765, P14778, Q9UL17, P23771, P84022, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, PLCG1, CD4, LCK, STAT1, STAT6, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, HSP90AB1, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.818 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.869 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.783 | P06737 | PYGL | Glycogen phosphorylase, liver form | P42226 | STAT6 | Signal transducer and activator of transcription 6 | 0.852 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.717 | Q13547 | HDAC1 | Histone deacetylase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.816 | P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.73 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.762 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.738 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q13547 | HDAC1 | Histone deacetylase 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.817 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.861 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.735 | P06737 | PYGL | Glycogen phosphorylase, liver form | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.753 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.767 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.85 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | -0.77 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 |
| Tolvaptan | hsa04660 | T cell receptor signaling pathway | 1.23E-11 | 17 | P01375, Q9UDY8, Q04759, P42338, P10747, O95267, Q08881, P19174, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, PIK3CB, CD28, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | P01375 | TNF | Tumor necrosis factor | 0.759 | P14780 | MMP9 | Matrix metalloproteinase-9 | P01375 | TNF | Tumor necrosis factor | 0.897 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.767 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.723 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q04759 | PRKCQ | Protein kinase C theta type | -0.787 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | 0.794 | P06737 | PYGL | Glycogen phosphorylase, liver form | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.73 | P14780 | MMP9 | Matrix metalloproteinase-9 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.792 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.806 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.8 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.855 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.812 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.746 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | P14780 | MMP9 | Matrix metalloproteinase-9 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.745 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | P14780 | MMP9 | Matrix metalloproteinase-9 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06737 | PYGL | Glycogen phosphorylase, liver form | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.72 | P14780 | MMP9 | Matrix metalloproteinase-9 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.742 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q13547 | HDAC1 | Histone deacetylase 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.816 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.816 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.92 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.793 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.806 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.816 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.778 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | P06737 | PYGL | Glycogen phosphorylase, liver form | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.815 | P14780 | MMP9 | Matrix metalloproteinase-9 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.75 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.781 |
| Tolvaptan | hsa04664 | Fc epsilon RI signaling pathway | 6.97E-03 | 4 | P04141, P07948, P19174, P09917 | CSF2, LYN, PLCG1, ALOX5 | More | | Tolvaptan | hsa04668 | TNF signaling pathway | 4.74E-02 | 3 | Q99941, P01584, O95429 | CREBL1, IL1B, BAG4 | More | | Tolvaptan | hsa04710 | Circadian rhythm | 2.43E-02 | 1 | O15516 | CLOCK | More | | Tolvaptan | hsa04713 | Circadian entrainment | 2.18E-02 | 4 | P0DP23, P62873, P63218, P50151 | CALM1, GNB1, GNG5, GNG10 | More | | Tolvaptan | hsa04714 | Thermogenesis | 6.01E-04 | 8 | Q16539, P51828, P62753, P33121, P12074, O15239, Q16718, O14521 | MAPK14, ADCY7, RPS6, ACSL1, COX6A1, NDUFA1, NDUFA5, SDHD | More | | Tolvaptan | hsa04723 | Retrograde endocannabinoid signaling | 2.68E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | | Tolvaptan | hsa04724 | Glutamatergic synapse | 1.57E-02 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Tolvaptan | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | Tolvaptan | hsa04726 | Serotonergic synapse | 3.80E-02 | 4 | P62873, P63218, P50151, P09917 | GNB1, GNG5, GNG10, ALOX5 | More | | Tolvaptan | hsa04727 | GABAergic synapse | 1.40E-03 | 5 | P62873, P63218, P50151, P48169, P15104 | GNB1, GNG5, GNG10, GABRA4, GLUL | More | | Tolvaptan | hsa04728 | Dopaminergic synapse | 4.78E-02 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | | Tolvaptan | hsa04730 | Long-term depression | 4.86E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Tolvaptan | hsa04742 | Taste transduction | 4.80E-02 | 1 | P48169 | GABRA4 | More | | Tolvaptan | hsa04744 | Phototransduction | 9.21E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Tolvaptan | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.62E-04 | 8 | P14778, P01584, P51828, Q13557, P19174, P42338, P24723, Q04759 | IL1R1, IL1B, ADCY7, CAMK2D, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Tolvaptan | hsa04911 | Insulin secretion | 2.03E-05 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | | Tolvaptan | hsa04912 | GnRH signaling pathway | 9.00E-03 | 7 | P51828, P18848, Q13557, Q16539, Q9Y6R4, Q14643, P22694 | ADCY7, ATF4, CAMK2D, MAPK14, MAP3K4, ITPR1, PRKACB | More | | Tolvaptan | hsa04915 | Estrogen signaling pathway | 5.03E-04 | 5 | Q99941, P18848, P51828, P07900, P11142 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8 | More | | Tolvaptan | hsa04918 | Thyroid hormone synthesis | 1.69E-03 | 4 | P51828, Q99941, P18848, P02768 | ADCY7, CREBL1, ATF4, ALB | More | | Tolvaptan | hsa04920 | Adipocytokine signaling pathway | 4.72E-02 | 4 | P33121, Q04759, Q9Y4H2, P01375 | ACSL1, PRKCQ, IRS2, TNF | More | | Tolvaptan | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | Tolvaptan | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Tolvaptan | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Tolvaptan | hsa04925 | Aldosterone synthesis and secretion | 2.51E-05 | 5 | Q99941, P18848, P51828, Q13557, P23634 | CREBL1, ATF4, ADCY7, CAMK2D, ATP2B4 | More | | Tolvaptan | hsa04926 | Relaxin signaling pathway | 3.34E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Tolvaptan | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Tolvaptan | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.09E-03 | 7 | Q14643, P51828, P22694, P23771, Q99941, P18848, P10415 | ITPR1, ADCY7, PRKACB, GATA3, CREBL1, ATF4, BCL2 | More | | Tolvaptan | hsa04932 | Non-alcoholic fatty liver disease | 3.62E-02 | 3 | P49841, Q16718, O14521 | GSK3B, NDUFA5, SDHD | More | | Tolvaptan | hsa04934 | Cushing syndrome | 1.09E-05 | 5 | Q99941, P18848, P51828, O15169, Q13557 | CREBL1, ATF4, ADCY7, AXIN1, CAMK2D | More | | Tolvaptan | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Tolvaptan | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | | Tolvaptan | hsa04966 | Collecting duct acid secretion | 4.48E-02 | 1 | P00918 | CA2 | More | | Tolvaptan | hsa04971 | Gastric acid secretion | 1.48E-02 | 3 | P51828, P15311, Q13557 | ADCY7, VIL2, CAMK2D | More | | Tolvaptan | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Tolvaptan | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | | Tolvaptan | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Tolvaptan | hsa05010 | Alzheimer disease | 2.07E-02 | 7 | Q92542, P05496, P12074, O75460, P01584, O15169, P45880 | NCSTN, ATP5G1, COX6A1, ERN1, IL1B, AXIN1, VDAC2 | More | | Tolvaptan | hsa05012 | Parkinson disease | 1.77E-02 | 6 | P60604, P19174, P0DP23, Q71U36, Q13509, P68371 | UBE2G2, PLCG1, CALM1, TUBA1A, TUBB3, TUBB2C | More | | Tolvaptan | hsa05020 | Prion disease | 1.37E-03 | 11 | P01584, P46531, P11142, Q16718, O14521, P05496, P12074, P45880, P49841, Q99941, Q16539 | IL1B, NOTCH1, HSPA8, NDUFA5, SDHD, ATP5G1, COX6A1, VDAC2, GSK3B, CREBL1, MAPK14 | More | | Tolvaptan | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Tolvaptan | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Tolvaptan | hsa05031 | Amphetamine addiction | 6.41E-03 | 3 | Q13557, Q99941, P18848 | CAMK2D, CREBL1, ATF4 | More | | Tolvaptan | hsa05032 | Morphine addiction | 1.06E-03 | 5 | P62873, P63218, P50151, Q13370, P48169 | GNB1, GNG5, GNG10, PDE3B, GABRA4 | More | | Tolvaptan | hsa05033 | Nicotine addiction | 2.43E-02 | 1 | P48169 | GABRA4 | More | | Tolvaptan | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Tolvaptan | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 6.09E-06 | 9 | Q16539, P25963, Q13488, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, NFKBIA, TCIRG1, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Tolvaptan | hsa05130 | Pathogenic Escherichia coli infection | 3.19E-02 | 6 | Q71U36, P16333, Q13509, P68371, Q14344, P25963 | TUBA1A, NCK1, TUBB3, TUBB2C, GNA13, NFKBIA | More | | Tolvaptan | hsa05132 | Salmonella infection | 1.44E-03 | 10 | P25963, P08238, Q13546, Q13489, O75369, O60282, Q71U36, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, RIPK1, BIRC3, FLNB, KIF5C, TUBA1A, TUBB3, TUBB2C, VPS41 | More | | Tolvaptan | hsa05133 | Pertussis | 2.35E-03 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Tolvaptan | hsa05134 | Legionellosis | 1.49E-03 | 5 | P25963, P11215, P11142, P09341, P19875 | NFKBIA, ITGAM, HSPA8, CXCL1, CXCL2 | More | | Tolvaptan | hsa05140 | Leishmaniasis | 1.41E-06 | 12 | P13612, O75015, P14598, P11215, P42224, P13765, O60603, P25963, P01375, P49006, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, ITGAM, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, MARCKSL1, MAPK14, NCF4 | More | | Tolvaptan | hsa05143 | African trypanosomiasis | 4.81E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Tolvaptan | hsa05144 | Malaria | 1.54E-02 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Tolvaptan | hsa05145 | Toxoplasmosis | 1.28E-02 | 4 | Q16539, P10415, Q13489, P13765 | MAPK14, BCL2, BIRC3, HLA-DOB | More | | Tolvaptan | hsa05146 | Amoebiasis | 1.21E-08 | 12 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Tolvaptan | hsa05150 | Staphylococcus aureus infection | 5.34E-03 | 8 | P0C0L4, P21730, P21462, O75015, P13765, Q16581, P13646, P12838 | C4A, C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, KRT13, DEFA4 | More | | Tolvaptan | hsa05152 | Tuberculosis | 1.81E-02 | 4 | P48382, P10415, P13765, Q16539 | RFX5, BCL2, HLA-DOB, MAPK14 | More | | Tolvaptan | hsa05160 | Hepatitis C | 4.55E-02 | 3 | O00501, P29728, P01106 | CLDN5, OAS2, MYC | More | | Tolvaptan | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | Tolvaptan | hsa05163 | Human cytomegalovirus infection | 3.87E-04 | 15 | P25963, P62873, P63218, P50151, Q14643, P0DP23, Q14344, P49841, P14778, P25025, Q16539, P04637, O00463, P30101, P01568 | NFKBIA, GNB1, GNG5, GNG10, ITPR1, CALM1, GNA13, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5, PDIA3, IFNA21 | More | | Tolvaptan | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 8.62E-05 | 10 | P01568, P42224, P25963, P62873, P63218, P50151, P19174, P07948, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GNB1, GNG5, GNG10, PLCG1, LYN, CSF2, CALM1 | More | | Tolvaptan | hsa05168 | Herpes simplex virus 1 infection | 3.79E-02 | 9 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, Q13398, O75820 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, ZNF211, ZNF189 | More | | Tolvaptan | hsa05169 | Epstein-Barr virus infection | 1.02E-03 | 16 | P13765, P01106, Q13547, O00463, P16070, P10415, Q16539, P07948, Q13761, P24522, Q8WV28, P01375, O60603, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, CD44, BCL2, MAPK14, LYN, RUNX3, GADD45A, BLNK, TNF, TLR2, CD3E, CD3G, CD247 | More | | Tolvaptan | hsa05170 | Human immunodeficiency virus 1 infection | 1.19E-02 | 8 | P62873, P63218, P50151, P0DP23, P30101, P01568, P25963, P19174 | GNB1, GNG5, GNG10, CALM1, PDIA3, IFNA21, NFKBIA, PLCG1 | More | | Tolvaptan | hsa05200 | Pathways in cancer | 1.99E-03 | 15 | P08238, P42224, P25963, P19174, P43246, P84022, P20585, P62873, P63218, P50151, Q14344, O75293, P0DP23, P01568, P14784 | HSP90AB1, STAT1, NFKBIA, PLCG1, MSH2, SMAD3, MSH3, GNB1, GNG5, GNG10, GNA13, GADD45B, CALM1, IFNA21, IL2RB | More | | Tolvaptan | hsa05202 | Transcriptional misregulation in cancer | 1.15E-08 | 23 | Q12778, Q15532, Q13315, P41732, P14780, P27930, Q15744, Q16548, Q13489, Q13077, Q15652, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P68431, Q13547, Q92769, P12980, P24522 | FOXO1, SS18, ATM, TSPAN7, MMP9, IL1R2, CEBPE, BCL2A1, BIRC3, TRAF1, JMJD1C, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, HDAC1, HDAC2, LYL1, GADD45A | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q12778 | FOXO1 | Forkhead box protein O1 | 0.795 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q15532 | SS18 | Protein SSXT | -0.772 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | Q15532 | SS18 | Protein SSXT | -0.829 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q13315 | ATM | Serine-protein kinase ATM | 0.723 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P41732 | TSPAN7 | Tetraspanin-7 | 0.703 | P06737 | PYGL | Glycogen phosphorylase, liver form | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.917 | P14780 | MMP9 | Matrix metalloproteinase-9 | P14780 | MMP9 | Matrix metalloproteinase-9 | 1 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.942 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P14780 | MMP9 | Matrix metalloproteinase-9 | -0.746 | P06737 | PYGL | Glycogen phosphorylase, liver form | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.881 | P14780 | MMP9 | Matrix metalloproteinase-9 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.851 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.924 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q15744 | CEBPE | CCAAT/enhancer-binding protein epsilon | 0.7 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.967 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.921 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.913 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.751 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.701 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.832 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.783 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.758 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.712 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q15652 | JMJD1C | Probable JmjC domain-containing histone demethylation protein 2C | 0.754 | P06737 | PYGL | Glycogen phosphorylase, liver form | O15550 | UTX | Lysine-specific demethylase 6A | 0.724 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | O15550 | UTX | Lysine-specific demethylase 6A | 0.73 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | O15550 | UTX | Lysine-specific demethylase 6A | -0.778 | P06737 | PYGL | Glycogen phosphorylase, liver form | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.73 | P14780 | MMP9 | Matrix metalloproteinase-9 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.89 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | P06737 | PYGL | Glycogen phosphorylase, liver form | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.73 | P14780 | MMP9 | Matrix metalloproteinase-9 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.89 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | P06737 | PYGL | Glycogen phosphorylase, liver form | P05164 | MPO | Myeloperoxidase | 0.858 | P14780 | MMP9 | Matrix metalloproteinase-9 | P05164 | MPO | Myeloperoxidase | 0.812 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P05164 | MPO | Myeloperoxidase | 0.711 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | P05164 | MPO | Myeloperoxidase | 0.711 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P05164 | MPO | Myeloperoxidase | -0.866 | P06737 | PYGL | Glycogen phosphorylase, liver form | P12838 | DEFA4 | Neutrophil defensin 4 | 0.7 | P14780 | MMP9 | Matrix metalloproteinase-9 | P12838 | DEFA4 | Neutrophil defensin 4 | 0.858 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P12838 | DEFA4 | Neutrophil defensin 4 | 0.767 | P06737 | PYGL | Glycogen phosphorylase, liver form | P08246 | ELA2 | Neutrophil elastase | 0.817 | P14780 | MMP9 | Matrix metalloproteinase-9 | P08246 | ELA2 | Neutrophil elastase | 0.859 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.703 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P08246 | ELA2 | Neutrophil elastase | -0.76 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.742 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.752 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.765 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | 0.879 | P06737 | PYGL | Glycogen phosphorylase, liver form | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.847 | P14780 | MMP9 | Matrix metalloproteinase-9 | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.812 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.9 | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | -0.79 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13547 | HDAC1 | Histone deacetylase 1 | -0.742 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q92769 | HDAC2 | Histone deacetylase 2 | -0.746 | P14780 | MMP9 | Matrix metalloproteinase-9 | P12980 | LYL1 | Protein lyl-1 | 0.716 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P12980 | LYL1 | Protein lyl-1 | 0.782 | P06737 | PYGL | Glycogen phosphorylase, liver form | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.822 | P14780 | MMP9 | Matrix metalloproteinase-9 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.765 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.801 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.734 |
| Tolvaptan | hsa05203 | Viral carcinogenesis | 2.63E-03 | 7 | Q99941, P18848, P27348, Q15283, P61978, P62807, O60814 | CREBL1, ATF4, YWHAQ, RASA2, HNRPK, HIST1H2BC, H2BC12 | More | | Tolvaptan | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Tolvaptan | hsa05206 | MicroRNAs in cancer | 2.97E-03 | 6 | P15311, P21860, P61978, P46531, P63279, P22105 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB | More | | Tolvaptan | hsa05212 | Pancreatic cancer | 1.05E-02 | 4 | P42224, P37173, P84022, O75293 | STAT1, TGFBR2, SMAD3, GADD45B | More | | Tolvaptan | hsa05214 | Glioma | 4.75E-02 | 3 | P0DP23, P19174, O75293 | CALM1, PLCG1, GADD45B | More | | Tolvaptan | hsa05217 | Basal cell carcinoma | 1.43E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Tolvaptan | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Tolvaptan | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Tolvaptan | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.39E-06 | 12 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, O60603, P10747, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, CD28, PRKCQ, MAPK14, CD4 | More | | Tolvaptan | hsa05310 | Asthma | 2.81E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Tolvaptan | hsa05321 | Inflammatory bowel disease | 2.46E-10 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P42226, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, STAT6, GATA3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | O60603 | TLR2 | Toll-like receptor 2 | 0.836 | P14780 | MMP9 | Matrix metalloproteinase-9 | O60603 | TLR2 | Toll-like receptor 2 | 0.89 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60603 | TLR2 | Toll-like receptor 2 | 0.867 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | O60603 | TLR2 | Toll-like receptor 2 | -0.717 | P06737 | PYGL | Glycogen phosphorylase, liver form | P01375 | TNF | Tumor necrosis factor | 0.759 | P14780 | MMP9 | Matrix metalloproteinase-9 | P01375 | TNF | Tumor necrosis factor | 0.897 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | P14780 | MMP9 | Matrix metalloproteinase-9 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.714 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.73 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.736 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.861 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.768 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.742 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.738 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.808 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.861 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.735 | P06737 | PYGL | Glycogen phosphorylase, liver form | P42226 | STAT6 | Signal transducer and activator of transcription 6 | 0.852 | P06737 | PYGL | Glycogen phosphorylase, liver form | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.753 | P14780 | MMP9 | Matrix metalloproteinase-9 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.747 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.767 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.85 |
| Tolvaptan | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Tolvaptan | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Tolvaptan | hsa05332 | Graft-versus-host disease | 3.09E-06 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Tolvaptan | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Tolvaptan | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | | Tolvaptan | hsa05414 | Dilated cardiomyopathy | 2.60E-03 | 3 | P54284, P09493, P26678 | CACNB3, TPM1, PLN | More | | Tolvaptan | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Tolvaptan | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | | |